# 2025年11月11日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. TBC1D24相关性癫痫的临床病程与药物治疗反应

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41215607](https://pubmed.ncbi.nlm.nih.gov/41215607)
**期刊：** Epilepsia
**PMID：** 41215607
**DOI：** 10.1111/epi.70013

### 第一部分 原文与翻译

**英文原标题：** Clinical trajectories and medication response in TBC1D24-related epilepsies.

**英文摘要原文：**
OBJECTIVE: Biallelic variants in TBC1D24 represent a rare cause of epilepsy and neurodevelopmental disorders, including severe developmental and epileptic encephalopathies. Here, we present the first attempt to delineate the longitudinal disease histories and effectiveness of antiseizure medications (ASMs) in TBC1D24-related disorders.

METHODS: We performed an analysis of the electronic medical record data of 15 individuals with TBC1D24-related disorders. Using the Human Phenotype Ontology, we recorded neurological histories and medication responses across 197 patient-years of information.

RESULTS: Individuals with TBC1D24-related disorders presented with a range of seizure types with a median age at seizure onset of 3 months-most frequently (73%) with focal myoclonic seizures both sparing and impairing consciousness. We report the maximum prevalence (MP) of various features as percentages of individuals reporting a given phenotype at that time point, compared to all those with available data at that time point. MP of focal seizures was at 6.25 and 7.75 years of age (88%), myoclonic seizures (focal and generalized) between 9 and 10 years of age (80%), and status epilepticus at 9 and 11 months of age (90%). Individuals also presented with a range of movement disorders. The MP of non-epileptic myoclonus was 100% at 1 and 17 months of age, tremor at 14 months of age (67%), ataxia at 7.25 years of age (45%), and episodic hemiplegia at 3.25 years of age (20%). The use of phenobarbital, oxcarbazepine, and topiramate showed the most promise in seizure management when compared to other ASMs. Everolimus, phenobarbital, and oxcarbazepine proved more effective in maintaining seizure freedom or reducing seizure frequencies in focal and myoclonic seizures compared to other ASMs.

SIGNIFICANCE: TBC1D24-related disorders are characterized by severe and pharmacoresistant epilepsy, with status epilepticus, focal seizures, and myoclonic seizures early in life. This study offers novel insights into the longitudinal disease course and treatment response in TBC1D24-related disorders, a critical first step toward clinical trial readiness.

**中文摘要译文：**
目的：TBC1D24基因的双等位基因变异是导致癫痫和神经发育障碍（包括严重的发育性和癫痫性脑病）的一种罕见原因。本研究首次尝试描绘TBC1D24相关疾病的纵向病史以及抗惊厥药物（ASMs）的有效性。

方法：我们对15名TBC1D24相关疾病患者的电子病历数据进行了分析。我们利用人类表型本体论，记录了跨越197个患者-年的神经系统病史和药物反应。

结果：TBC1D24相关疾病患者表现出多种类型的癫痫发作，中位发病年龄为3个月——最常见（73%）的是局灶性肌阵挛发作，包括意识保留和意识受损两种情况。我们报告了各种特征的最大患病率（MP），即在特定时间点报告某一表型的个体百分比，并与该时间点所有有可用数据的个体进行比较。局灶性发作的最大患病率出现在6.25岁和7.75岁（88%），肌阵挛发作（局灶性和全身性）在9至10岁之间（80%），癫痫持续状态在9个月和11个月时（90%）。患者还表现出多种运动障碍。非癫痫性肌阵挛在1个月和17个月时的最大患病率为100%，震颤在14个月时为67%，共济失调在7.25岁时为45%，发作性偏瘫在3.25岁时为20%。与其他抗惊厥药物相比，苯巴比妥、奥卡西平和托吡酯在癫痫管理方面显示出最大的应用前景。在维持无发作状态或降低局灶性和肌阵挛性发作频率方面，依维莫司、苯巴比妥和奥卡西平被证明比其他抗惊厥药物更有效。

意义：TBC1D24相关疾病的特征是严重且耐药的癫痫，在生命早期即出现癫痫持续状态、局灶性发作和肌阵挛性发作。本研究为TBC1D24相关疾病的纵向病程和治疗反应提供了新的见解，是为临床试验准备迈出的关键第一步。

### 第二部分 AI 大师评价

本研究首次系统性地描绘了罕见病TBC1D24相关癫痫的纵向临床轨迹和药物反应。通过对15名患者长达197个患者-年的电子病历数据进行回顾性分析，研究不仅明确了不同年龄阶段癫痫发作类型和运动障碍的演变规律，还初步筛选出苯巴比妥、奥卡西平等潜在有效的抗惊厥药物。尽管样本量较小，但这项开创性工作为理解该疾病的自然史提供了宝贵见解，并为未来的临床试验设计奠定了关键基础。

---

## 2. 细胞外囊泡蛋白质组学研究发现可用于癫痫持续状态早期诊断的新型血液生物标志物

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41208302](https://pubmed.ncbi.nlm.nih.gov/41208302)
**期刊：** Epilepsia
**PMID：** 41208302
**DOI：** 10.1111/epi.70008

### 第一部分 原文与翻译

**英文原标题：** Extracellular vesicle proteomics identifies novel blood biomarkers for the early diagnosis of status epilepticus.

**英文摘要原文：**
OBJECTIVE: This study was undertaken to identify novel blood-based biomarkers associated with the early diagnosis of status epilepticus (SE) by exploring proteomic alterations in plasma extracellular vesicles (EVs).

METHODS: We conducted an observational and prospective study in a two-phase design: a discovery proteomic analysis of plasma EVs from 16 patients (eight with SE and eight matched non-SE), followed by a validation phase using basic immunodetection techniques in a separate cohort of 160 patients (80 SE, 80 non-SE) for selected proteins in plasma. Proteomic profiling was performed with liquid chromatography-tandem mass spectrometry, and protein interaction networks were explored using STRING and Cytoscape software platforms.

RESULTS: In the discovery phase, 2046 proteins were identified, and 977 met inclusion criteria. CDH1, APOC4, and IGHG2 showed the highest differential expression in SE patients. Network analysis revealed strong interactions involving SLC4A1 and SRC. In the validation cohort, levels of APOC4, CDH1, SLC4A1, and S100B were significantly higher in SE patients (p < .05). In the multivariate logistic regression model, only APOC4, S100B, and SLC4A1 remained independently associated with SE diagnosis. A combined model including these proteins predicted SE with 84.6% accuracy (95% confidence interval = 64.3%-94.9%). Other proteins, including NSE and HMGB1, showed no significant differences.

SIGNIFICANCE: This study identifies new plasma biomarkers that may support the early diagnosis of SE, particularly in emergency settings where access to electroencephalography is limited. These findings suggest potential applicability to clinical practice; nevertheless, prospective validation in independent and larger cohorts is required.

**中文摘要译文：**
目的：本研究旨在通过探索血浆细胞外囊泡（EVs）的蛋白质组学改变，鉴定与癫痫持续状态（SE）早期诊断相关的新型血液生物标志物。

方法：我们采用两阶段设计，进行了一项观察性、前瞻性研究：首先对16例患者（8例SE患者和8例匹配的非SE患者）的血浆EVs进行发现蛋白质组学分析，随后在一个独立的160例患者队列（80例SE患者，80例非SE患者）中，使用基础免疫检测技术对血浆中的特定蛋白进行验证。蛋白质组学分析采用液相色谱-串联质谱法进行，并使用STRING和Cytoscape软件平台探索蛋白质相互作用网络。

结果：在发现阶段，共鉴定出2046种蛋白质，其中977种符合纳入标准。在SE患者中，CDH1、APOC4和IGHG2的差异表达最为显著。网络分析揭示了涉及SLC4A1和SRC的强相互作用。在验证队列中，SE患者的APOC4、CDH1、SLC4A1和S100B水平显著升高（p < .05）。在多变量逻辑回归模型中，仅APOC4、S100B和SLC4A1与SE诊断保持独立相关。一个包含这些蛋白质的组合模型预测SE的准确率为84.6%（95%置信区间 = 64.3%-94.9%）。包括NSE和HMGB1在内的其他蛋白质未显示出显著差异。

意义：本研究鉴定出了新的血浆生物标志物，这些标志物可能有助于SE的早期诊断，尤其是在脑电图检查受限的急诊环境中。这些发现提示了其在临床实践中的潜在应用价值；然而，仍需在独立的、更大规模的队列中进行前瞻性验证。

### 第二部分 AI 大师评价

本研究通过先进的细胞外囊泡蛋白质组学技术，成功筛选并验证了一组与癫痫持续状态（SE）早期诊断相关的血浆生物标志物。研究设计严谨，从发现到验证，最终确定APOC4、S100B和SLC4A1的组合模型具有较高的诊断准确率。这项发现极具临床转化潜力，有望为缺乏脑电图条件的急诊环境提供一种快速、微创的辅助诊断手段，从而改善患者预后。尽管研究结论尚需更大规模的前瞻性队列验证，但它为SE的诊断新策略开辟了重要方向。

---

## 3. 临床推理：一名因急性脑病和失语症就诊的59岁男性

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41100786](https://pubmed.ncbi.nlm.nih.gov/41100786)
**期刊：** Neurology
**PMID：** 41100786
**DOI：** 10.1212/WNL.0000000000214299

### 第一部分 原文与翻译

**英文原标题：** Clinical Reasoning: A 59-Year-Old Man With Acute-Onset Encephalopathy and Aphasia.

**英文摘要原文：**
Assessing patients with acute encephalopathy presents significant challenges because of the wide range of underlying causes. This complexity is further intensified when seizures are involved, making the selection of effective management even more critical. In this case, a 59-year-old man was evaluated at the emergency department for acute-onset confusion and aphasia, which later on was complicated by seizures. Stroke was initially ruled out, and valproate therapy was instituted. EEG showed slow background activity, CSF was normal, and brain MRI showed bilateral cortical T2 hyperintensities with diffusion restriction involving the insula and cingulate gyrus. The neuroimaging findings narrowed the differential and pointed to the final diagnosis. In this case, we walk through the differential diagnosis of acute encephalopathy, highlighting the importance of a systematic diagnostic approach and considering the wide variety of etiologies, with an emphasis on those with specific treatments. The presence of key clinical and radiologic data guides the clinician to reach the final diagnosis.

**中文摘要译文：**
由于潜在病因繁多，急性脑病患者的评估工作充满挑战。当病情涉及癫痫发作时，其复杂性会进一步加剧，使得选择有效的治疗方案变得至关重要。在本案例中，一名59岁男性因急性意识模糊和失语症在急诊科接受评估，其后并发癫痫。初步排除了卒中，并开始使用丙戊酸盐治疗。脑电图（EEG）显示背景活动减慢，脑脊液（CSF）正常，脑部磁共振成像（MRI）显示双侧皮质T2高信号，伴有累及岛叶和扣带回的弥散受限。神经影像学发现缩小了鉴别诊断范围，并指向了最终诊断。在本案例中，我们逐步探讨了急性脑病的鉴别诊断过程，强调了系统性诊断方法的重要性，并考虑了多种病因，重点关注那些有特效治疗方法的病因。关键临床和影像学数据的出现引导临床医生得出最终诊断。

### 第二部分 AI 大师评价

本研究以一例急性脑病伴失语症的复杂病例为载体，旨在展示系统性的临床鉴别诊断过程。文章通过详细描述患者的临床进程、实验室检查及关键的神经影像学发现，强调了特定MRI特征（双侧岛叶和扣带回的弥散受限）在缩小鉴别诊断范围中的决定性作用。该案例分析不仅为临床医生处理类似疑难杂症提供了清晰的思维框架，也凸显了对于存在特异性治疗方法的病因进行早期识别的临床重要性，具有很高的教学价值和实践指导意义。

---

## 4. 结节性硬化症患者的药物抵抗性癫痫：考虑手术治疗不宜过迟

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41100782](https://pubmed.ncbi.nlm.nih.gov/41100782)
**期刊：** Neurology
**PMID：** 41100782
**DOI：** 10.1212/WNL.0000000000214367

### 第一部分 原文与翻译

**英文原标题：** Drug-Resistant Epilepsy in Individuals With Tuberous Sclerosis Complex: Don't Wait Too Long to Consider Surgery.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

本文献虽然没有提供摘要，但其标题已明确揭示核心论点，即对于结节性硬化症（TSC）相关的药物抵抗性癫痫患者，应及早考虑外科手术。此文很可能是一篇社论或专家评论，旨在呼吁临床医生转变观念，避免因犹豫而延误最佳手术时机，从而改善患者的长期预后。其临床价值在于为神经科医生和癫痫专家提供了强有力的实践指导，强调了在治疗复杂癫痫时优化干预时机的重要性，可能对现行临床路径产生积极影响。

---

## 5. 结节性硬化症患者药物抵抗性癫痫的切除性手术治疗：一项前瞻性全国多中心队列研究

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41100778](https://pubmed.ncbi.nlm.nih.gov/41100778)
**期刊：** Neurology
**PMID：** 41100778
**DOI：** 10.1212/WNL.0000000000214260

### 第一部分 原文与翻译

**英文原标题：** Resective Surgery for Drug-Resistant Epilepsy in Patients With Tuberous Sclerosis Complex: A Prospective Nationwide Multicenter Cohort Study.

**英文摘要原文：**
BACKGROUND AND OBJECTIVES: Resective surgery is an effective treatment for tuberous sclerosis complex (TSC)-related drug-resistant epilepsy (DRE). However, high-level evidence validating the effectiveness and safety of this technique is lacking. This study aimed to provide prospective multicenter data comparing resective surgery with medicine treatments.

METHODS: This prospective cohort study included patients with TSC-related DRE who were suitable for resective surgery from 2019 to 2022 were identified from 21 centers in China. After collection, patients who underwent resective surgery were entered into the surgery group, whereas those who refused surgery and continued medicine treatment were included in the medicine group. Follow-ups for ≥2 years tracked seizure control, IQ, quality of life (QOL), antiseizure medications (ASMs), and adverse events. Propensity score matching (PSM) was performed to balance baseline demographics and clinical characteristics. Seizure-freedom probabilities were estimated using Kaplan-Meier analysis, and the mixed effects Cox proportional hazards model assessed the risk of seizure recurrence alongside other covariates.

RESULTS: Each group comprised 100 patients with a total median age of 6.70 years (interquartile range, 3.73-12.80), and 35% were female patients. PSM-adjusted seizure-freedom rates in the surgery group were 77%, 67%, 66%, and 67% at 1-, 2-, 3-, and 4-year follow-ups, respectively, compared with 13%, 7%, 6%, and 4% in the medicine group. The surgery group had a higher probability of achieving seizure freedom. Resective surgery was identified as the strongest independent predictor reducing post-collection seizure recurrence (hazard ratio, 0.10; 95% CI, 0.05-0.17;  < 0.0001). Significant improvements in IQ and QOL were found at the 2-year follow-up, along with reductions in ASMs across all follow-ups after surgery ( < 0.01). Outstanding tubers were the independent factor for postoperative low seizure recurrence. Serious complications were not found, and no significant differences in adverse events were observed.

DISCUSSION: Resective surgery demonstrates significantly higher effectiveness than medicine in seizure control and improvements of IQ and QOL in patients with TSC-related DRE, achieving a 1-year seizure-freedom rate of 77%. Furthermore, the safety of resective surgery is comparable with that of medicine. Outstanding tubers on MRI is an independent predictor of postoperative seizure freedom. Selection bias and possible confounding by site are limitations of this study.

TRIAL REGISTRATION INFORMATION: Registered with ClinicalTrials.gov as TRE-RES. Registration number: NCT04198181. Date of the registration submitted to the registry: November 10, 2019. Date of first patient enrollment: December 12, 2019.

CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that resective surgery provides better seizure control, and improved IQ and quality of life, than medication alone in patients with TSC.

**中文摘要译文：**
背景与目的：切除性手术是治疗结节性硬化症（TSC）相关药物抵抗性癫痫（DRE）的有效方法。然而，目前缺乏高级别证据来验证该技术的有效性和安全性。本研究旨在提供前瞻性多中心数据，以比较切除性手术与药物治疗的效果。

方法：本项前瞻性队列研究纳入了2019年至2022年间来自中国21个中心的适合接受切除性手术的TSC相关DRE患者。入组后，接受切除性手术的患者被分入手术组，而拒绝手术并继续接受药物治疗的患者则被纳入药物组。研究进行了为期≥2年的随访，以追踪癫痫控制情况、智商（IQ）、生活质量（QOL）、抗癫痫药物（ASMs）使用情况及不良事件。采用倾向性评分匹配（PSM）以平衡基线人口统计学和临床特征。使用Kaplan-Meier分析估计无癫痫发作概率，并采用混合效应Cox比例风险模型评估癫痫复发风险及其他协变量的影响。

结果：两组各包含100名患者，总中位年龄为6.70岁（四分位距为3.73-12.80岁），其中35%为女性。经PSM校正后，手术组在1年、2年、3年和4年随访时的无癫痫发作率分别为77%、67%、66%和67%，而药物组则分别为13%、7%、6%和4%。手术组实现无癫痫发作的概率更高。切除性手术被确定为降低入组后癫痫复发的最强独立预测因子（风险比为0.10；95% CI为0.05-0.17；P < 0.0001）。术后2年随访时发现患者的IQ和QOL有显著改善，并且在所有术后随访期间抗癫痫药物的使用均有减少（P < 0.01）。边界清晰的结节是术后癫痫低复发率的独立影响因素。未发现严重并发症，两组在不良事件方面无显著差异。

讨论：对于TSC相关的DRE患者，切除性手术在癫痫控制、IQ和QOL改善方面的效果显著优于药物治疗，其1年无癫痫发作率达到77%。此外，切除性手术的安全性与药物治疗相当。MRI上边界清晰的结节是术后无癫痫发作的独立预测因子。本研究的局限性在于存在选择偏倚以及可能的研究中心间混杂因素。

试验注册信息：本研究在ClinicalTrials.gov注册，名称为TRE-RES。注册号：NCT04198181。注册提交日期：2019年11月10日。首例患者入组日期：2019年12月12日。

证据分类：本研究为III级证据，表明对于TSC患者，切除性手术在癫痫控制、IQ及生活质量改善方面优于单纯药物治疗。

### 第二部分 AI 大师评价

本研究通过一项大规模、前瞻性的全国多中心队列研究，直接比较了手术与药物治疗结节性硬化症相关药物抵抗性癫痫的长期效果。研究关键发现，切除性手术在癫痫控制、智商及生活质量改善方面远优于药物治疗，一年无发作率高达77%，且安全性相当。此项研究为该领域提供了重要的III级证据，有力支持了对符合条件的患者进行早期手术干预的临床决策，并指出了影像学上边界清晰的结节是预测良好预后的关键因素。

---

## 6. 儿童与成人镰状细胞贫血患者的脑血流量

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41092248](https://pubmed.ncbi.nlm.nih.gov/41092248)
**期刊：** Neurology
**PMID：** 41092248
**DOI：** 10.1212/WNL.0000000000214227

### 第一部分 原文与翻译

**英文原标题：** Cerebral Blood Flow in Children and Adults With Sickle Cell Anemia.

**英文摘要原文：**
BACKGROUND AND OBJECTIVES: Understanding age-related changes in cerebral blood flow (CBF, rate of blood delivery to brain tissue) in sickle cell anemia (SCA) is a prerequisite to incorporating CBF as a marker of brain health. CBF decreases from school-age through adulthood in nonanemic people. In SCA, CBF is generally increased to compensate for anemia, but knowledge of age-related norms is limited. We hypothesized that age-related CBF trajectories differ for SCA vs nonanemic healthy persons: CBF increases from childhood to early adulthood in SCA to compensate for reduced blood oxygen content and then plateaus because of reduced vasodilatory capacity with older age.

METHODS: Children and adults with SCA and race-matched controls (hemoglobin [Hb] AA) aged 6-45 years were enrolled in an observational cross-sectional study from 2014 to 2023 at an academic and community health center. History of overt stroke or arterial stenosis >50% were exclusions. Brain MRIs were performed at 3T with arterial-spin-labeling measurements of gray matter CBF. Regression analyses assessed how age, imaging markers of ischemia, Hb, and arterial oxygen saturation (SpO) related to CBF.

RESULTS: In 192 Black participants with SCA (N = 126; mean age = 18.7 ± 9.0 years, 52.4% female) or without SCA (N = 66; mean age = 22.4 ± 9.7 years, 54.5% female), total Hb was lower in SCA (mean Hb = 8.9 ± 1.3 g/dL) vs control (mean Hb = 13.4 ± 1.5 g/dL) participants ( < 0.001) and did not differ with age in the SCA group. SpO was reduced in SCA (median SpO = 96%; interquartile range [IQR] = 94-97.4%) vs controls (median SpO = 98%, IQR = 97-99%,  < 0.001). In SCA participants, SpO was lower in adults (median SpO = 95%, IQR = 94%-97%,  = 0.001) compared with children (SpO = 96.5%, IQR = 95%-98.2%). Regression analyses, including an interaction between age and group (SCA vs control), showed that CBF increases in SCA by 5.03 mL/100 g/min per decade (95% CI 1.70-8.37) and plateaus at approximately age 30-35 years. In controls, CBF decreased by -5.20 mL/100 g/min per decade (95% CI -8.96 to -1.94).

DISCUSSION: The divergent age dependency of CBF between SCA and non-anemic persons may be explained by a gradient of increasing CBF with age required to compensate for reductions in blood oxygen content in SCA, with possible exhaustion of cerebral vasodilatory abilities in the fourth decade of life. Longitudinal studies are needed.

**中文摘要译文：**
背景与目的：了解镰状细胞贫血（SCA）患者脑血流量（CBF，即血液输送至脑组织的速率）随年龄变化的规律，是将CBF作为脑健康标志物的前提。在非贫血人群中，CBF从学龄期到成年期呈下降趋势。在SCA患者中，CBF通常会增加以代偿贫血，但关于其年龄相关正常值的知识有限。我们假设SCA患者与非贫血健康人的CBF年龄相关轨迹不同：SCA患者的CBF从儿童期到成年早期会增加，以代偿血氧含量的降低，之后因年龄增长血管舒张能力下降而进入平台期。

方法：本研究为一项观察性横断面研究，于2014年至2023年间在一家学术与社区健康中心招募了6-45岁的SCA儿童与成人患者，以及种族匹配的对照组（血红蛋白[Hb] AA型）。有明显卒中史或动脉狭窄>50%的患者被排除在外。研究采用3T磁共振成像技术，通过动脉自旋标记方法测量灰质CBF。通过回归分析评估年龄、缺血影像学标志物、Hb和动脉血氧饱和度（SpO）与CBF的关系。

结果：在192名黑人参与者中（SCA组N = 126，平均年龄 = 18.7 ± 9.0岁，52.4%为女性；非SCA组N = 66，平均年龄 = 22.4 ± 9.7岁，54.5%为女性），SCA组的总Hb水平（平均Hb = 8.9 ± 1.3 g/dL）低于对照组（平均Hb = 13.4 ± 1.5 g/dL）（p < 0.001），且在SCA组内Hb水平不随年龄变化。SCA组的SpO水平较低（中位SpO = 96%；四分位距[IQR] = 94-97.4%），而对照组为（中位SpO = 98%，IQR = 97-99%，p < 0.001）。在SCA参与者中，成人的SpO水平（中位SpO = 95%，IQR = 94%-97%，p = 0.001）低于儿童（SpO = 96.5%，IQR = 95%-98.2%）。包含年龄与分组（SCA组 vs 对照组）交互作用的回归分析显示，SCA患者的CBF每十年增加5.03 mL/100 g/min（95% CI 1.70-8.37），并在约30-35岁时达到平台期。在对照组中，CBF每十年下降5.20 mL/100 g/min（95% CI -8.96 至 -1.94）。

讨论：SCA患者与非贫血者之间CBF对年龄的依赖性差异，可能解释为SCA患者为代偿血氧含量下降，需要随年龄增长而增加CBF，而在生命的第四个十年可能出现脑血管舒张能力的耗竭。未来需要进行纵向研究。

### 第二部分 AI 大师评价

本研究旨在明确镰状细胞贫血（SCA）患者脑血流量（CBF）与年龄的独特关系。研究创新性地采用动脉自旋标记MRI技术，揭示了与健康对照组CBF随年龄下降的趋势相反，SCA患者的CBF从儿童期至成年早期呈代偿性增加，并在约30-35岁达到平台期。这一关键发现提示了SCA患者脑血管为应对长期缺氧而产生的适应性变化及其潜在的“耗竭”风险，为将CBF作为评估SCA脑健康和干预效果的动态生物标志物提供了重要依据，具有显著的临床科研价值。

---

## 7. 临床前动物研究中的统计方法与设计同其成功转化为II期临床试验的关联性研究

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41082697](https://pubmed.ncbi.nlm.nih.gov/41082697)
**期刊：** Neurology
**PMID：** 41082697
**DOI：** 10.1212/WNL.0000000000214250

### 第一部分 原文与翻译

**英文原标题：** Association of Statistical Methodology and Design in Preclinical Animal Studies With Successful Translation Into Clinical Phase 2 Trials.

**英文摘要原文：**
BACKGROUND AND OBJECTIVES: Preclinical-to-clinical translational failure is common in neurologic research. Reasons for translational failure are complex and multifaceted, but it is increasingly recognized that translational decision making may be influenced by preclinical work that is overly optimistic, due to a lack of scientific rigor. Previous research has demonstrated that statistical errors are common in preclinical research, yet results of preclinical null hypothesis significance testing contribute to the body of evidence used to evaluate whether a new intervention is a candidate for translation. However, no empirical investigations exist yet that compare positive and negative clinical trials on the statistical soundness of contributing studies. The aim of this study was to explore, for 3 neurologic indications (multiple sclerosis, Parkinson disease, epilepsy), whether negative clinical trials show a higher prevalence of statistical misapplication in preceding animal experiments, compared with positive human trials.

METHODS: A modified meta-research, case-control design with multistep systematic search was used. Phase 2 clinical trials (completed January 1, 2010-October 31, 2020) were identified on ClinicalTrials.gov. Best practice methods were used to systematically search MEDLINE and Embase for animal experiments preceding the start of each human trial, for each intervention and disease. Statistical reporting and decision-making data were gathered from animal articles by collectors blinded to human trial outcome. Rates of statistical mistakes were compared between animal articles preceding positive vs negative human trials using weighted percentages and CIs.

RESULTS: The final sample included 24 trials (8 negative) and 70 associated rodent studies. Animal studies preceding negative human trials had higher rates of misapplication of solely cross-sectional statistical tests to longitudinal data (93% [95% CI 83-100] vs 66% [95% CI 47-82]) and of the use of plots that concealed continuous data distributions (98% [95% CI 95-100] vs 71% [95% CI 51-91]), indicating possible mishandling of continuous data.

DISCUSSION: Statistical practice in animal studies was generally poor or not well reported, with rates of some statistical mistakes occurring more frequently before negative trials than positive trials. This was an exploratory study with a highly selected sample, yet it suggests that translational decision making should include evaluation of the quality of preclinical statistical practice.

**中文摘要译文：**
背景与目的：在神经科学研究中，从临床前到临床的转化失败现象十分普遍。转化失败的原因复杂且涉及多方面，但人们日益认识到，由于缺乏科学严谨性，过于乐观的临床前研究工作可能会影响转化决策。既往研究已表明，统计错误在临床前研究中很常见，然而临床前研究的零假设显著性检验结果却构成了评估新干预措施是否可被转化的证据体系的一部分。但是，目前尚无实证研究就支持性研究的统计稳健性对阳性和阴性临床试验进行比较。本研究旨在针对三种神经系统疾病（多发性硬化症、帕金森病、癫痫），探讨与阳性人体试验相比，阴性临床试验其之前的动物实验中是否存在更高普遍性的统计误用情况。

方法：本研究采用了一种改良的元研究、病例对照设计，并结合了多步系统性检索。研究人员在ClinicalTrials.gov网站上筛选出II期临床试验（完成于2010年1月1日至2020年10月31日）。采用最佳实践方法，针对每项干预措施和疾病，在MEDLINE和Embase数据库中系统检索了每个人体试验开始前的动物实验。由对人体试验结果不知情的采集员从动物研究文献中收集统计报告和决策数据。使用加权百分比和置信区间（CI）比较了导致阳性与阴性人体试验的动物研究文献中统计错误的发生率。

结果：最终样本包括24项临床试验（其中8项为阴性）和70项相关的啮齿类动物研究。在导致阴性人体试验的动物研究中，将纯粹的横断面统计检验错误应用于纵向数据的比率更高（93% [95% CI 83-100] vs 66% [95% CI 47-82]），并且使用掩盖连续数据分布的图表的比率也更高（98% [95% CI 95-100] vs 71% [95% CI 51-91]），这表明可能存在对连续数据的不当处理。

讨论：动物研究中的统计实践普遍较差或报告不佳，且在阴性试验之前，某些统计错误的发生率比阳性试验之前更高。尽管这是一项样本选择性高的探索性研究，但其结果表明，转化决策应包括对临床前研究统计实践质量的评估。

### 第二部分 AI 大师评价

该研究创新性地采用元研究的病例对照设计，旨在探究临床前动物研究的统计严谨性与后续II期临床试验成功率之间的关联。研究核心发现，那些最终导向阴性临床结果的研究，其所依据的临床前动物实验存在更普遍的统计误用现象，例如不当使用统计检验和数据可视化方法。这项探索性研究首次从实证角度揭示了临床前统计质量可能是影响转化医学成败的关键因素之一，提示在启动昂贵的临床试验前，对前期动物研究的统计方法进行严格审查具有重大的科研与临床价值。

---

速递结束，祝您工作愉快！